Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 25, 2026Drug DeliveryOpen Access

Bioengineered extracellular vesicles integrating anti-EphA2 recognition and oxaliplatin delivery for pancreatic cancer therapy

View Full Paper
Ask AI
Bookmark
Share

Authors

SCShi-Wei ChaoWTWan-Chi TsaiYCYung-Han Chang

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Chao et al. (2026) studied this question.

synapsesocial.com/papers/6ab60f7f406bf401c146801ahttps://doi.org/10.1080/10717544.2026.2728215
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Enhancing precision targeting of ovarian cancer tumor cells in vivo through extracellular vesicle engineering2024 · 4 citations
  2. 2Maximizing oxaliplatin's impact on EGFR + colorectal cancer through targeted extracellular vesicles2024 · 1 citations
  3. 3Scalable Engineering of Bio‐Manufactured Extracellular Vesicles for Selective Delivery in Ovarian Cancer Patient‐Derived Models2026
  4. 4Maximizing Oxaliplatin's Impact on EGFR+ Colorectal Cancer Through Targeted Extracellular Vesicles2024
  5. 5HER2-targeted doxorubicin-loaded cell-derived extracellular vesicles induce apoptosis of breast cancer cells via ROS/TXNIP pathway activation2026